Recombinant Adenoviruses Which Express the EBV Major Membrane Antigen GP340/220 Induce Persistent EBV-Neutralizing Antibodies in Rabbits

  • T. Ragot
  • E. Tosoni-Pitonni
  • S. Finerty
  • A. J. Morgan
  • M. Perricaudet
Part of the Experimental Biology and Medicine book series (EBAM, volume 24)


EBV is etiologicaly associated with endemic Burkitt’s lymphoma and undifferenciated nasopharyngeal carcinoma (NPC), causes infectious mononucleosis and has been implicated in lymphomas arising in immunosuppressed patients and AIDS bearers (1,2). The possibility of controlling the course of these diseases by vaccination has been discussed for a long time (3), especially in the case of NPC which affects up to 2% of the whole male population in southern China and therefore represents a major world cancer problem. Two of the major glycoproteins gp340/gp220, both encoded by the same gene (4) and expressed on the outer surface of virions and infected cells, are capable of eliciting in vitro neutralizing antibodies to EBV (5). A subunit vaccine based on purified gp340 has been successfully used to protect cottontop tamarins against EBV-induced lymphoma (6,7). Nevertheless, the use of recombinant live viruses as vaccine vectors has many advantages for future human trials. These include the ability to produce gp340 in the absence of EBV DNA, posttranslational modification and antigen presentation provided by the host’s own cell, broad spectrum of immune response, induction of long teen immunological memory and low cost. Previous experiments have been carried out using recombinant Vaccinia (8) and Varicella-zoster (9) viruses. Protection against EBV-induced lymphoma was achieved using a Vaccinia recombinant laboratory strain but not a vaccine strain (10). We wish to develop a live vaccine against EBV based on recombinant human Adenovirus (Ad) type 5, producing the EBV envelope glycoprotein gp340/220. Indeed, Ad strains have been used widely in vaccination programs in the U.S. military and have a good safety record (11). Expression cassettes containing an Ad strong promoter followed by the coding region for gp340/220, or by the sequence of a cDNA clone corresponding to the spliced mRNA coding region for gp220, or by these constructions deleted for the region corresponding to the transmembrane and cytoplasmic domains of the protein, were introduced by homologous recombination into the AdS. These viruses where named respectively Adgp340, Adgp220, Adgp340D and Adgp220D.


Recombinant Adenovirus Subunit Vaccine Infectious Mononucleosis Vaccine Vector Major Glycoprotein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Epstein M.A. and Achong B.G. (eds) (1979). “The Epstein-Barr Virus”. Berlin, Springer-Verlag.CrossRefGoogle Scholar
  2. 2.
    Epstein M.A. and Achong B.G. (eds) (1986). “The Epstein-Barr Vinas: Recent Advances” London, Heidemann.Google Scholar
  3. 3.
    Epstein M.A.; J. Natl. Cancer Inst. 56,697 (1976).PubMedGoogle Scholar
  4. 4.
    Beisel C. etal.J.Virol. 54, 665 (1985).PubMedGoogle Scholar
  5. 5.
    Thorley-Lawson D.A. et al.; Proc. Natl. Acad. Sci. 77, 5307 (1980).PubMedCrossRefGoogle Scholar
  6. 6.
    Epstein M.A. et al.; Nature 318, 387 (1985).Google Scholar
  7. 7.
    Morgan A.J. et al.;J. Gen Virol. 69, 2093 (1988).PubMedCrossRefGoogle Scholar
  8. 8.
    Mackett M. and Arrand J; EMBO J. 4, 3229 (1985).PubMedGoogle Scholar
  9. 9.
    Lowe S.R.,et al.; Proc. Natl Arad. Sci. 84, 3896 (1987).CrossRefGoogle Scholar
  10. 10.
    Morgan A.J. et al.; J. Med. Virol. 25, 189 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    Chanock al.; J. American. Medical. Association.195, 151 (1966).CrossRefGoogle Scholar
  12. 12.
    Tosoni-Pittoni et al.; Biochem. Biophys. Res. Commun. 158, 676 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    De Schryver A. et al.; Int. J. Cancer 13,353 (1974).PubMedCrossRefGoogle Scholar
  14. 14.
    Whang Y. et al.; J. Virol. 61, 1796 (1987).PubMedGoogle Scholar
  15. 15.
    Tanner J. et al.; J. Virol. 62, 4452 (1988).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • T. Ragot
    • 1
  • E. Tosoni-Pitonni
    • 1
  • S. Finerty
    • 2
  • A. J. Morgan
    • 2
  • M. Perricaudet
    • 1
  1. 1.Laboratoire de Génétique des Virus Oncogènes, UA1301 CNRSInstitut Gustave RoussyVillejuifUK
  2. 2.Department of PathologyUniversity of Bristol, Medical SchoolBristolUK

Personalised recommendations